Novartis (SWX:NOVN) is back in focus after the US FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, materially widening the therapy’s eligible patient pool.
See our latest analysis for Novartis.
Against this backdrop, Novartis shares trade at CHF125.98, with a 90 day share price return of 10.8% and a year to date share price return of 16.11%. The 1 year total shareholder return of 38.01% points to momentum that has been building over a longer period.
If you are looking beyond Novartis for other potential healthcare leaders using advanced data and automation, this is a good moment to scan the market with the 130 healthcare AI stocks
Bulls see the Pluvicto approval as validation of Novartis and its CHF125.98 share price. Bears question how much is already reflected. The valuation work below helps clarify which side current numbers lean toward.
Most Popular Narrative: 10% Undervalued
The most followed narrative pegs Novartis fair value at CHF126.14, almost exactly in line with the current CHF125.98 share price, yet still labels the stock modestly undervalued once future cash flows are discounted at 3.94%.
Novartis' robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies, potentially accelerating future earnings and margin growth as new high-value products launch.
Curious how this future growth story justifies today’s price tag? The narrative leans heavily on steady top line expansion, fatter margins, and a lower future earnings multiple to arrive at that fair value. The exact mix of those assumptions might surprise you.
Result: Fair Value of CHF126.14 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that future growth story for Novartis could be challenged if key drugs lose exclusivity faster than expected or if pricing pressure in Europe and China intensifies.
Find out about the key risks to this Novartis narrative.
Next Steps
Given the mixed sentiment around Novartis, this is a useful moment to study the facts directly, run your own checks, and decide where you stand. To weigh both sides of the argument in one place, start with the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Novartis?
If Novartis has your attention today, this is the moment to widen your lens and spot other opportunities before the crowd catches up.
- Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations through the 263 high quality undervalued stocks
- Strengthen your income pillar by reviewing high yielding companies that aim to balance payout and resilience using the 440 dividend fortresses
- Prioritise capital preservation by focusing on companies with steadier profiles and lower risk scores via the 298 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com